がんにおける二重特異性抗体の世界市場2019-2023

【英語タイトル】Global Bispecific Antibodies for Cancer Market 2019-2023

Technavioが出版した調査資料(IRTNTR31178)・商品コード:IRTNTR31178
・発行会社(調査会社):Technavio
・発行日:2019年4月17日
・ページ数:117
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、がんにおける二重特異性抗体の世界市場について調査・分析し、市場概要、市場環境、がんにおける二重特異性抗体市場規模、ターゲット別(CD19/CD3、CD30/CD16A)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・がんにおける二重特異性抗体の世界市場概要
・がんにおける二重特異性抗体の世界市場環境
・がんにおける二重特異性抗体の世界市場動向
・がんにおける二重特異性抗体の世界市場規模
・がんにおける二重特異性抗体の世界市場:業界構造分析
・がんにおける二重特異性抗体の世界市場:ターゲット別(CD19/CD3、CD30/CD16A)
・がんにおける二重特異性抗体の世界市場:地域別市場規模・分析
・がんにおける二重特異性抗体の北米市場規模・予測
・がんにおける二重特異性抗体のヨーロッパ・中東・アフリカ市場規模・予測
・がんにおける二重特異性抗体のアジア太平洋市場規模・予測
・がんにおける二重特異性抗体の主要国分析
・がんにおける二重特異性抗体の世界市場:意思決定フレームワーク
・がんにおける二重特異性抗体の世界市場:成長要因、課題
・がんにおける二重特異性抗体の世界市場:競争環境
・がんにおける二重特異性抗体の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market

The advantages of bispecific antibodies over monoclonal antibodies is one of the key factors expected to propel the market growth during the forecast period. The limitations of monoclonal antibodies such as limited binding abilities for specific antigens have encouraged researchers to improve and increase the efficacy of the molecules and enhance their function by developing antibodies with two or more targets. Bispecific antibodies can simultaneously address two different antigens, which are sufficient to target two trails involved in cancer pathogenesis, and therefore, provide advantages over monoclonal antibodies therapy. Hence, the advantages of bispecific antibodies will drive the growth of the market in the upcoming years. Technavio’s analysts have predicted that the bispecific antibodies for cancer market will register a CAGR of over 30% by 2023.

Market Overview

Increasing prevalence of cancer

The increase in the prevalence of cancer across the world will fuel the demand for bispecific antibodies to treat these cancers, thereby driving the growth of the market.

The high cost of drug

Most of the cancer patients in low- and middle-income countries fail to complete the course of drug therapy as these drugs are priced beyond their reach.

For the detailed list of factors that will drive and challenge the growth of the bispecific antibodies for cancer market during 2019-2023, view our report.

Competitive Landscape

The market appears to be moderately fragmented with the presence of several market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: CUSTOMER LANDSCAPE

PART 07: MARKET SEGMENTATION BY TARGET

Market segmentation by target

Comparison by target

CD19/CD3 – Market size and forecast 2018-2023

CD30/CD16A – Market size and forecast 2018-2023

Market opportunity by target

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Market trends

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

Astella Pharma Inc.

Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd.

Merus

Regeneron Pharmaceuticals, Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global oncology therapeutics market

Exhibit 02: Segments of global oncology therapeutics market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Bispecific antibodies for cancer under development

Exhibit 10: Five forces analysis 2018

Exhibit 11: Five forces analysis 2023

Exhibit 12: Bargaining power of buyers

Exhibit 13: Bargaining power of suppliers

Exhibit 14: Threat of new entrants

Exhibit 15: Threat of substitutes

Exhibit 16: Threat of rivalry

Exhibit 17: Market condition – Five forces 2018

Exhibit 18: Customer landscape

Exhibit 19: Target – Market share 2018-2023 (%)

Exhibit 20: Comparison by target

Exhibit 21: CD19/CD3 – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: CD19/CD3 – Year-over-year growth 2019-2023 (%)

Exhibit 23: CD30/CD16A – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: CD30/CD16A – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by target

Exhibit 26: Market share by geography 2018-2023 (%)

Exhibit 27: Geographic comparison

Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 29: North America – Year-over-year growth 2019-2023 (%)

Exhibit 30: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 32: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 33: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 34: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 35: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 36: Key leading countries

Exhibit 37: Market opportunity

Exhibit 38: Impact of drivers and challenges

Exhibit 39: Pipeline for bispecific antibodies for cancer treatment

Exhibit 40: Vendor landscape

Exhibit 41: Landscape disruption

Exhibit 42: Vendors covered

Exhibit 43: Vendor classification

Exhibit 44: Market positioning of vendors

Exhibit 45: Amgen Inc. – Vendor overview

Exhibit 46: Amgen Inc. – Product segments

Exhibit 47: Amgen Inc. – Organizational developments

Exhibit 48: Amgen Inc. – Geographic focus

Exhibit 49: Amgen Inc. – Key offerings

Exhibit 50: Astella Pharma Inc. – Vendor overview

Exhibit 51: Astella Pharma Inc. – Business segments

Exhibit 52: Astella Pharma Inc. – Organizational developments

Exhibit 53: Astella Pharma Inc. – Key offerings

Exhibit 54: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. – Vendor overview

Exhibit 55: Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd. – Key offerings

Exhibit 56: Merus – Vendor overview

Exhibit 57: Merus – Product segments

Exhibit 58: Merus – Key offerings

Exhibit 59: Regeneron Pharmaceuticals, Inc. – Vendor overview

Exhibit 60: Regeneron Pharmaceuticals, Inc. – Business segments

Exhibit 61: Regeneron Pharmaceuticals, Inc. – Organizational developments

Exhibit 62: Regeneron Pharmaceuticals, Inc. – Key offerings

Exhibit 63: Validation techniques employed for market sizing



【掲載企業】

Amgen Inc., Astella Pharma Inc., Ben Kang Biopharmaceutical (Shenzhen) Co., Ltd., Merus, Regeneron Pharmaceuticals, Inc.

★調査レポート[がんにおける二重特異性抗体の世界市場2019-2023] (コード:IRTNTR31178)販売に関する免責事項を必ずご確認ください。
★調査レポート[がんにおける二重特異性抗体の世界市場2019-2023]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆